Skip to content
8-K

Material Event

Coherus Oncology, Inc. CHRS

0001104659-25-111484

← back to feed
Filed
Nov 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted 2024 · Dec 31, 2024 114.55M sh
Shares Diluted 2023 · Dec 31, 2023 94.16M sh
Operating Cash Flow 2024 · Dec 31, 2024 −$20.44M
Operating Cash Flow 2023 · Dec 31, 2023 −$174.88M
Cash And Equivalents 2024 · Dec 31, 2024 $125.99M
Cash And Equivalents 2023 · Dec 31, 2023 $102.89M
Cash And Equivalents 2022 · Dec 31, 2022 $63.55M
Stockholders Equity 2024 · Dec 31, 2024 −$131.99M
Stockholders Equity 2023 · Dec 31, 2023 −$193.43M
Stockholders Equity 2022 · Dec 31, 2022 −$137.42M
Current Liabilities 2024 · Dec 31, 2024 $282.98M
Current Liabilities 2023 · Dec 31, 2023 $331.77M
Total Liabilities 2024 · Dec 31, 2024 $580.52M
Total Liabilities 2023 · Dec 31, 2023 $823.03M
Current Assets 2024 · Dec 31, 2024 $341.58M
Current Assets 2023 · Dec 31, 2023 $475.63M
Total Assets 2024 · Dec 31, 2024 $448.53M
Total Assets 2023 · Dec 31, 2023 $629.6M
Eps Diluted 2024 · Dec 31, 2024 $0.25
Eps Diluted 2023 · Dec 31, 2023 −$2.53
Eps Basic 2024 · Dec 31, 2024 $0.25
Eps Basic 2023 · Dec 31, 2023 −$2.53
Sga Expense 2024 · Dec 31, 2024 $125.48M
Sga Expense 2023 · Dec 31, 2023 $120.46M
Rd Expense 2024 · Dec 31, 2024 $91.83M
Rd Expense 2023 · Dec 31, 2023 $96.11M
Operating Income 2024 · Dec 31, 2024 −$199.65M
Operating Income 2023 · Dec 31, 2023 −$215.79M
Cost Of Revenue 2024 · Dec 31, 2024 $8.73M
Cost Of Revenue 2023 · Dec 31, 2023 $438K